In Brief: OTC vaginal contraceptives
This article was originally published in The Tan Sheet
Executive Summary
OTC vaginal contraceptives: Sen. Patty Murray (D-Wash.) and Reps. Connie Morella (R-Md.) and Nita Lowey (D-N.Y.) oppose FDA's proposed rule to require NDAs for OTC vaginal contraceptives in a June 30 letter to FDA Commissioner David Kessler. "We believe the government should be encouraging the development of new contraceptive products and expanding women's reproductive choice, not discouraging businesses from manufacturing existing products that have been shown to be safe and effective," they said. Industry also has strongly opposed the FDA proposal ("The Tan Sheet" June 19, pp. 9-12)...